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ABSTRACT 
   Schizophrenia is a mental disorder painful with prevalence of about 1% in the world.  Nowadays, there is 
no experimental test aiding the accurate diagnosis of schizophrenic patients but recently quantitative 
determination of some serum proteins led to many investigations on the roles of these in neuropsychiatric.  
In the present study, our aim is to quantitative determination ApoA1 and IgM between 134 schizophrenic 
patients and 127 healthy control persons. Schizophrenia patients were selected from the Tehran Razi 
hospital.  The age (p=0.53) and sex distributions of schizophrenic patients were similar to those of control 
persons. We measured ApoA1 and IgM levels by immunoturbidimetry method. P<0.05 was considered 
significant.  ApoA1 showed a significant decrease in serum (p=0.00) and IgM to be significantly increased 
(p=0.00). 
Furthermore, female patients showed an increase IgM more than males. These results for ApoA1 and IgM 
support other reports.  Decrease ApoaA1 confirmed the relationship of lipid metabolism in schizophrenia 
patients, also increase IgM evaluate the impact of treatment. This report can help to identify disease markers 
and treatment such as immunoglobulin therapy or regulate lipid metabolism. It can be imagined that 
immunoglobulin therapy more effective in the female patients than male and need to expand about them. 
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INTRODUCTION 
     Schizophrenia is a mental disorder, which 
affects 1% of the world population and   is 
characterized by a lack of perception and 
expression of reality that can lead to 
complications such as the lack of rational 
communication behavior and speech, excessive 
isolation and withdrawal, delirium and 
hallucinations. The person usually   hears voices, 
sees scenes and touch's things that others cannot 
understand [2]. Surveys show that one of the 
principle risk factors for schizophrenia is genetic 
susceptibility, and some genes may make people 
more at risk for this disease [3-5] and the most 
significant is VCH RNA gene [6].  
Environmental factors such as being born in 
winter, problems during pregnancy and birth 
complications, including influenza, Rh factor, 
viral infections (Retrovirus) and malnutrition 
during fetal life and geographical alterations 
influence disease [2,7] . In addition to above 
factors, like many other diseases, schizophrenia is 
associated with metabolism dysfunction. As the 
brain is main organ affected in diseases of CNS 
and because of the high concentration of lipids are 
in brain, lipid metabolism dysfunction is involved 
in the disease pathogenesis [8]. 
Extensive studies of lipid metabolism dysfunction 
have shown performance and changes in 
apolipoproteins, including, ApoE, Apo A1, Apoc, 
ApoD in patients with schizophrenia [9-11], also 
change of ApoA1 and ApoE have been observed 
in some of the other mental disorders [12, 13]. 
Apolipoprotein through activation or inhibition of 
enzymes involved in lipid metabolism and 
binding lipoproteins by lipoprotein receptors on 
the cell surface play an important role in the 
transmission lipids [7]. In the present study, we 
evaluated ApoA1 with due to attention to the role 
of apolipoproteins and available facilities. ApoA1 
 




is a major protein component of HDL whit 243-
245 amino acid and 28000KD weight.  ApoA1 
active enzyme lecithin cholesterol acyl transferase 
(LCAT) and leads flow of cholesterol from tissues 
to the liver [14, 15].  
Following above noted, researchers have focused 
on the interaction of the central nervous system 
(CNS) and immune system in patients with 
schizophrenia over the past three decades such as 
viral diseases in the foetus which will cause 
automatically immunity against parts of the brain 
and increase the risk of schizophrenia. 
Schizophrenia is caused by changes in the 
immune system and the central nervous system to 
produce antibodies against antigens and can 
disrupt neuronal function [6].  
Antibodies are part of immune responses vast 
network that can recognize and eliminate foreign 
substances [17]. The studies conducted so far, the 
changes have been reported in the 
immunoglobulins such as IgM that first antibody 
is against pathogens in the body, therefor their 
changes is measurable earlier compare with else 
immunoglobulins. However, laboratory diagnosis 
of schizophrenia is still unclear and present study 
evaluated new laboratory diagnosis of ApoA1 and 
IgM. 
 
STUDY POPULATION AND METHODS 
      All study subjects consisted of 133 patients 
with schizophrenia (62 males and 71 females; 
mean age:  41±6.2 years) and healthy controls (59 
males and 69 females; mean age:  40±6.1).we 
recruited all patients from Tehran Razi Hospital 
and healthy controls from volunteer's subjects.  
Schizophrenia of patients was confirmed by 
specialists, according to DMS-IV diagnostic 
criteria and healthy controls were recruited with 
history of mental health. The study samples were 
filled questionnaires based on age, sex, weight, 
smoking history and education level. 
The blood samples were collected and 
immediately transported to the biochemistry 
laboratory of Pasteur Institute then were isolated 
serum samples by centrifugation (3000 rpm, 30 
min at 4 C) and stored at -80 C. 
ApoA1 and IgM were measured with commercial 
kits by autoanalyzer biochemistry and were 
determined using the immunoturbidimetry 
method.  
Statistical analysis 
Statistical analysis were performed by SPSS 16 
and significance was set at P < 0.05.normality 
parametric analyzes were performed with Mann-
Whitney test.  
 
RESULTS 
     A total of 133 samples patients and 118 
healthy groups were compared in this study, and 
results showed a correlation between ApoA1and 
IgM.  
 ApoA1 in patients was decreased, but IgM was 
increased (P values of both 0.001) (table 1)  
Furthermore, IgM levels in females, showed a 
significant increasing more than males (p = 0.005) 
(Table 2). 
 
Table 1: statistical analysis of ApoA1 and IgM between 
control group and schizophrenia patients 




Wilcoxon W 10825/000 12056/500 
Z -10/826 -7/729 
P value 
 (t test)   
0/001 0/001 
 
Table 2: Statistical analysis of ApoA1 and IgM due to sex in 









2197/500 1812/000 1576/500 
Wilcoxon W 4753/500 3765/000 3529/500 
Z -0/016 -1/756 -2/817 
P value  
(t test )   




     The brain of Schizophrenia patients is heavily 
involved, imaging results using DTI (diffusion 
tensor imaging) and MTI (magnetization transfer 
imaging) have show significant variations in the 
brains of people with schizophrenia [3]. 
The studies have shown that because central 
nervous system dysfunction in patients with 
schizophrenia is a disorder of lipid metabolism. 
Brain has highest concentration of lipids [8] and 
lipids play a role in making myelin and 
oligodendrocyt function at brain prefrontal cortex 
 




and anterior cingulated cortex of patients with 
schizophrenia, and this contributes strongly to the 
pathogenesis of schizophrenia [22].  
In patients with schizophrenia, associated with the 
regulation of lipid metabolism, including 
apolipoproteins Apo, A, C, D, E have received 
much attention [20]. 
Last studies have shown  ApoA1 levels   in the 
cerebrospinal fluid - CSF and in peripheral tissues 
such as liver, blood cells and serum is reduced 
[14].these These studies show that the reduction 
in cerebrospinal fluid (CSF) reflected in 
peripheral tissues, and its value can be evaluated 
in their blood [9]. 
ApoA1 levels were measured in the present study 
showed significantly reduction; In addition, there 
was a little loss in female patients than males. 
Therefore, female patients showed more 
metabolism dysfunctions. 
However, this correlation  was weak but the new 
finding, so more researchs and greater numbers of 
samples can be achieved beneficial results. 
Blalock's research suggested that the immune 
system as a sensory organ for external 
stimulations that the nervous system did not 
recognize it [23], even the immune response of a 
person with mental states, such as grief, loss, 
loneliness, etc., change [16]. 
In schizophrenia patients, presence of antibodies 
against central nervous system neurotransmitters 
such as dopamine, serotonin, cardiolipin, antigen's 
cytoplasmic and nuclear antigens, has been 
shown. This finding supported the increase of 
dopamine. 
Since dopamine is a specific component of brain 
cells, and as a target for antibodies in the brain 
and leads to increase more antibodies that these 
antibodies can block or regulate a function of 
neurons.  
However, antibodies against antigens of the 
central nervous system, are produced both in 
normal subjects and patients with schizophrenia, 
but  schizophrenia cause changes in the nervous 
system and one of these changes is increasing of 
dopamine so Brain's antigens, leading to a further 
increase in the amount of natural antibodies, 
including IgM [24,17]. 
However, these differences in immune reactivity 
between healthy subjects and patients with 
schizophrenia, can affect brain antigens and 
pathogenesis [6]. 
IgM levels elevated in patients with 8 weeks of 
drug therapy has been shown [17, 25] Chong and 
colleagues have been shown IgM elevated 
regardless of whether or not patients are treated 
[18].Sane Sane and colleagues showed increasing 
of IgM in mental disorders and patients who were 
not treated [26] even there are also reports 
indicating no change in the amount of IgM [19]. 
These differences were due to non-specific IgM in 
the immune system, under different conditions 
[17]. Today, there are high-precision methods 
such as nephelometry and immunoturbidimetry 
that IgM level is, measure carefully.  
In the present study, significant increasing of IgM 
have been seen , Even in females, the increase 
was higher in previous studies.  Disease in 
women, mostly associated with immunological 
changes more than lipid metabolism and in male 
patients decreased ApoA1 was higher. In addition, 
IgM  used as biomarkers for evaluate of the 




    ApoA1 and IgM were compared patients and 
controls changes.  Therefore, these two 
parameters as diagnostic tests used in conjunction 
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